PRODIGE23, long term results now published

Krishan Jethwa, Assistant Professor of Radiation Oncology at Mayo Clinic, shared a paper by Thierry Conroy et al. on X:

“PRODIGE23.

Long term results now published!

T3-4 rectal adenocarcinoma Randomized:

CRT to FOLFOX mFOLFIRINOX to CRT to FOLFOX

Improved OS!!!

Looking forward to JANUS clarifying if TNT with FOLFIRINOX vs. FOLFOX improves cCR and/or DFS/OS.”

Source: Krishan Jethwa/X

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.

Authors: T. Conroy, F. Castan, P.-L. Etienne, E. Rio, N. Mesgouez-Nebout, L. Evesque, V. Vendrely, X. Artignan, O. Bouché, D. Gargot, V. Boige, N. Bonichon-Lamichhane, C. Louvet, C. Morand, C. de la Fouchardière, A. Boilève, M. Delaye, S. Gourgou, V. Pezzella, and C. Borg.